Open Access

Association between the levels of CGI‑58 and lipoprotein lipase in the placenta of patients with preeclampsia

  • Authors:
    • Jianxin Dong
    • Miao Wang
    • Jie Gao
    • Jie Liu
    • Yan Chen
  • View Affiliations

  • Published online on: August 5, 2021     https://doi.org/10.3892/etm.2021.10563
  • Article Number: 1129
  • Copyright: © Dong et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Preeclampsia is an idiopathic disease of pregnancy, which seriously endangers the life of both the mother and the infant. The pathogenesis of preeclampsia has not been fully elucidated, although it is generally considered to be associated with abnormal lipid metabolism during pregnancy. Comparative gene identification‑58 (CGI‑58) and lipoprotein lipase (LPL) are involved in the first step of triglyceride hydrolysis and serve an important role in lipid transport in the placenta. The present study aimed therefore to investigate the association between CGI‑58 and LPL in the placentas of patients with or without preeclampsia and to evaluate blood lipid levels. The patient cohort was divided into two groups, pregnant women with preeclampsia and normal pregnant women (control). According to biochemical analyses, reverse transcription‑quantitative PCR, immunohistochemistry analysis and western blotting, the expression of CGI‑58 and LPL in the placenta was detected, the blood lipid levels were evaluated and other clinical data were collected. Compared with the control group, triglycerides (TGs), low density lipoprotein‑cholesterol (LDL‑C), apolipoprotein B (ApoB) and atherosclerotic index (AI) were significantly higher in the preeclampsia group, whereas high density lipoprotein‑­cholesterol (HDL‑C) and apolipoprotein A (ApoA) were significantly lower (P<0.05). Furthermore, the expression levels of CGI‑58 and LPL in the placental tissue of the preeclampsia group was significantly lower than that of the control group (P<0.05). Linear correlation analysis demonstrated that there was a positive association between CGI‑58 and LPL (r=0.602; P<0.05), that CGI‑58 was positively associated with HDL‑C (r=0.63; P<0.01) but negatively associated with TG and ApoB (r=0.840; P<0.01; and r=0.514; P<0.05, respectively), that LPL was positively associated with HDL‑C (r=0.524; P<0.01) but negatively associated with TG and AI (r=0.659; P<0.01; and r=0.496; P<0.01, respectively). These results suggested that the expression of CGI‑58 and LPL in the placenta was associated with the pathogenesis of preeclampsia and maternal lipids and the risk of preeclampsia was increased with decreasing expression levels of CGI‑58 and LPL. Hence, CGI‑58 and LPL may be used as important indicators for the diagnosis of preeclampsia and for the prevention of preeclampsia in pregnant women.
View Figures
View References

Related Articles

Journal Cover

October-2021
Volume 22 Issue 4

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Dong J, Wang M, Gao J, Liu J and Chen Y: Association between the levels of CGI‑58 and lipoprotein lipase in the placenta of patients with preeclampsia. Exp Ther Med 22: 1129, 2021
APA
Dong, J., Wang, M., Gao, J., Liu, J., & Chen, Y. (2021). Association between the levels of CGI‑58 and lipoprotein lipase in the placenta of patients with preeclampsia. Experimental and Therapeutic Medicine, 22, 1129. https://doi.org/10.3892/etm.2021.10563
MLA
Dong, J., Wang, M., Gao, J., Liu, J., Chen, Y."Association between the levels of CGI‑58 and lipoprotein lipase in the placenta of patients with preeclampsia". Experimental and Therapeutic Medicine 22.4 (2021): 1129.
Chicago
Dong, J., Wang, M., Gao, J., Liu, J., Chen, Y."Association between the levels of CGI‑58 and lipoprotein lipase in the placenta of patients with preeclampsia". Experimental and Therapeutic Medicine 22, no. 4 (2021): 1129. https://doi.org/10.3892/etm.2021.10563